Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC-MMC in Peritoneal Carcinomatosis From Solid Gastrointestinal Malignancies
NCT07487168Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitomycin c in peritoneal carcinomatosis (PC), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Aug 2026; status: recruiting.
02
Drugs
mitomycin c
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT07487168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487168.